Compare BioNTech SE - ADR (BNTX) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Ferrari NV — how do they compare? BioNTech SE - ADR trades at $90 (market cap $22.86B), while Ferrari NV trades at $376.29 (market cap $65.00B). The key difference: Ferrari NV is far larger — about 2.8× BioNTech SE - ADR's market cap, and Ferrari NV pays a 1.14% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | RACE | |
|---|---|---|
Market Cap | $22.86B | $65.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $517.65 |
52-Week Low | $83.89 | $314.63 |
Enterprise Value | $6.53B | $66.21B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Ferrari (RACE) trades at $372.98, down 0.97% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong profitability with a net income margin of 22.19% and robust revenue growth from $5.1B in 2022 to $7.1B in 2025. Recent news highlights the company's ongoing share buyback program and strategic moves in the EV space, though the Luce model has faced some market skepticism.
The outlook remains positive with a consensus price target of $467.50, implying significant upside. Key opportunities include pricing power and margin strength, while risks involve execution on EV strategy and high valuation multiples. Earnings consistently beat expectations, supporting the bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
